Table 1 Baseline characteristics of samples from the TCGA database.
Clinical features | Training set | Internal validation set | P-value | ||
|---|---|---|---|---|---|
N | % | N | % | ||
Age | 0.213 | ||||
≥ 56 | 180 | 55.2% | 68 | 48.9% | |
< 56 | 146 | 44.8% | 71 | 51.1% | |
ER | 0.597 | ||||
Negative | 85 | 26.1% | 33 | 23.7% | |
Positive | 241 | 73.9% | 106 | 76.3% | |
PR | 0.214 | ||||
Negative | 118 | 36.2% | 42 | 30.2% | |
Positive | 208 | 63.8% | 97 | 69.8% | |
HER2 | 0.230 | ||||
Negative | 246 | 75.5% | 112 | 80.6% | |
Positive | 80 | 24.5% | 27 | 19.4% | |
T-stage of primary tumor | 0.832 | ||||
T1 | 97 | 29.8% | 40 | 28.8% | |
T2 | 229 | 70.2% | 99 | 71.2% | |
Lymph node status | 0.993 | ||||
Without metastasis | 169 | 51.8% | 72 | 51.8% | |
With metastasis | 157 | 48.2% | 67 | 48.2% | |
Subtypes | 0.522 | ||||
HR+/HER2− | 188 | 57.7% | 89 | 64.0% | |
HR+/HER2+ | 57 | 17.5% | 21 | 15.1% | |
HR−/HER2+ | 23 | 7.1% | 6 | 4.3% | |
HR−/HER2− | 58 | 17.8% | 23 | 16.5% | |
Pathological types | 0.391 | ||||
Invasive ductal carcinoma | 282 | 86.5% | 116 | 83.5% | |
Invasive lobular carcinoma | 44 | 13.5% | 23 | 16.5% | |
